Stockscreener 앱 받기
579.54
0.38%
-2.20
시간 외 거래:
579.54
전일 마감가:
$581.74
열려 있는:
$581.17
하루 거래량:
306.23K
Relative Volume:
0.61
시가총액:
$24.60B
수익:
$3.17B
순이익/손실:
$1.29B
주가수익비율:
21.39
EPS:
27.0947
순현금흐름:
$1.01B
1주 성능:
-2.89%
1개월 성능:
+0.33%
6개월 성능:
+25.36%
1년 성능:
+88.12%
1일 변동 폭
$574.84
$584.71
1주일 범위
$561.20
$599.00
52주 변동 폭
$272.12
$609.35
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
579.54 | 24.69B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
16.64 | 51.87B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.25 | 41.70B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.02 | 40.34B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.34 | 32.26B | 9.51B | 2.64B | 2.14B | 6.0361 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics director Mesa Nilda sells $150,139 in stock - Investing.com
Varda Space, United Therapeutics to test lung drugs in orbit - qz.com
United Therapeutics (UTHR) Partners with Varda Space Industries for Innovative Drug Development - GuruFocus
Varda and United Therapeutics Partner to Crystallize Protein in Space for Rare Lung Disease Therapies - geneonline.com
Varda Space, United Therapeutics partner on drug development By Investing.com - Investing.com South Africa
Varda Space, United Therapeutics partner on drug development - Investing.com
Could this be the moment that drug manufacturing takes off in orbit? - Ars Technica
Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease - ChartMill
United Therapeutics Corp (UTHR) News, Articles, Events & Latest Updates - Stocktwits
United Therapeutics CFO James Edgemond sells $5.7m in stock - Investing.com
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy - Quantisnow
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference - ChartMill
Pharma CEO's Role In Ex-Exec's Contract Permits Deposition - Law360
Hedge Fund and Insider Trading News: Ken Griffin, Scott Bessent, Warren Buffett, CastleKnight Management, Saba Capital, Brevan Howard, TCI Fund Management, Aminex PLC (AEX), United Therapeutics Corp (UTHR), and More - Insider Monkey
United Therapeutics (UTHR) Set to Showcase New Data at American Thoracic Society Conference - GuruFocus
United Therapeutics chairperson & CEO Rothblatt sells $5.5m in stock - Investing.com UK
United Therapeutics CFO Edgemond sells $5.7m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CFO Edgemond sells $5.7m in stock - Investing.com India
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026 - ChartMill
United Therapeutics Corporation (UTHR) Stock Analysis: A 17.28% Upside Potential Beckons Investors - DirectorsTalk Interviews
MNKD stock records biggest single-day gains in over 5 years, breaches a key technical milestone – what’s driving this rally? - MSN
MannKind (MNKD) Is Up 25.4% After Mixed Q1 Results and Expanded United Therapeutics Partnership – What's Changed - Yahoo Finance
UTHR Maintained by RBC Capital -- Price Target Lowered to $701 - GuruFocus
United Therapeutics EVP Paul Mahon sells $4.87m in common stock By Investing.com - Investing.com India
United Therapeutics’ Earnings Call Signals Next Growth Phase - The Globe and Mail
United Therapeutics EVP Paul Mahon sells $4.87m in common stock - Investing.com
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2026 Earnings Call Transcript - Insider Monkey
Transcript: United Therapeutics Q1 2026 Earnings Conference Call - Sahm
UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook - TradingView
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More - 24/7 Wall St.
United Therapeutics reports Q1 EPS $5.82, consensus $6.86 - TipRanks
UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook - StockStory
United Therapeutics: Q1 Earnings Snapshot - theheraldreview.com
United Therapeutics outlines $4B revenue run rate by end of 2027 as ralinepag and IPF plans advance - msn.com
BTIG reiterates Neutral on United Therapeutics stock after Q1 miss - Investing.com UK
BTIG reiterates Neutral on United Therapeutics stock after Q1 miss By Investing.com - Investing.com South Africa
United Therapeutics CEO Rothblatt sells $5.47m in stock By Investing.com - Investing.com South Africa
United Therapeutics CEO Rothblatt sells $5.47m in stock - Investing.com
United Therapeutics Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
MSN Money - MSN
TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $660 - Moomoo
United Therapeutics Q1 2026 slides: IPF breakthrough offsets revenue miss - Investing.com
Earnings call transcript: United Therapeutics misses Q1 2026 earnings forecast By Investing.com - Investing.com Nigeria
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.16%
3.38%
자본화:
|
볼륨(24시간):